To the Editor Precision oncology offers thrilling therapeutic possibilities, as demonstrated by Cobain and colleagues1 in their cohort study. We do, however, have concerns regarding the generalizability of their findings, in particular, the expansive recommendation for “directed germline testing in all patients with advanced cancer.”1(p525)
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Dunn C, Gately L, Gibbs P. Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time? JAMA Oncol. 2021;7(8):1246. doi:10.1001/jamaoncol.2021.1904
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.